HCC-2, LKN-1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q16663 |
---|---|
Species | Human |
Sequence | QFTNDAETEL MMSKLPLENP VVLNSFHFAA DCCTSYISQS IPCSLMKSYF ETSSECSKPG VIFLTKKGRQ VCAKPSGPGV QDCMKKLKPY SI |
Purity | > 95% by SDS-PAGE analysis. |
Endotoxin Level | < 0.2 EU/ µg, determined by LAL method. |
Formulation | Lyophilized after extensive dialysis against PBS. |
Reconstitution | Reconstituted in ddH2O at 100 µg/mL. |
Gene ID | 6359 |
---|---|
Other Names | C-C motif chemokine 15, Chemokine CC-2, HCC-2, Leukotactin-1, LKN-1, MIP-1 delta, Macrophage inflammatory protein 5, MIP-5, Mrp-2b, NCC-3, Small-inducible cytokine A15, CCL15(22-92), CCL15(25-92), CCL15(29-92), CCL15, MIP5, NCC3, SCYA15 |
Target Background | Macrophage Inflammatory Protein-5 (MIP-5/CCL15) is a chemokine originally identified in the human hemofiltrate, thus it is also named Hemofiltrate CC Chemokine-2 (HCC-2). MIP-5 belongs to the CCL chemokine family, and its receptors are G-protein coupled receptors CCR1 and CCR3, with CCR1 being the major one. MIP-5 is mainly expressed in heart and skeletal muscle, and CCR1 is expressed on Th1 and Th2 cells in human cord blood lymphocytes. In vivo, MIP-5 promotes the accumulation of immature myeloid cells and the expansion of metastatic foci in the lever. MIP-5 contributes to severe asthma, sarcoidosis, and atherosclerosis;however, MIP-5 can also inhibit stem cell proliferation, implicating its therapeutic potential as an alternative to high dose chemotherapy. Recombinant human MIP-5/CCL15 (rhMIP-5/CCL15) produced in E.coli is a single non-glycosylated polypeptide chain containing 92 amino acids. A fully biologically active molecule, rhMIP-5/CCL15 has a molecular mass of 10.2 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at . |
Name | CCL15 |
---|---|
Synonyms | MIP5, NCC3, SCYA15 |
Function | Chemotactic factor that attracts T-cells and monocytes, but not neutrophils, eosinophils, or B-cells. Acts mainly via CC chemokine receptor CCR1. Also binds to CCR3. CCL15(22-92), CCL15(25-92) and CCL15(29-92) are more potent chemoattractants than the CCL15. |
Cellular Location | Secreted. |
Tissue Location | Most abundant in heart, skeletal muscle and adrenal gland. Lower levels in placenta, liver, pancreas and bone marrow CCL15(22-92), CCL15(25-92) and CCL15(29-92) are found in high levels in synovial fluids from rheumatoid patients. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.